FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2622765713> ?p ?o ?g. }

• W2622765713 endingPage "e0178905" @default.
• W2622765713 startingPage "e0178905" @default.
• W2622765713 abstract "Noonan Syndrome with Multiple Lentigines (NSML, formerly LEOPARD syndrome) is an autosomal dominant RASopathy disorder manifesting in congenital heart disease. Most cases of NSML are caused by catalytically inactivating mutations in the protein tyrosine phosphatase (PTP), non-receptor type 11 (PTPN11), encoding the SH2 domain-containing PTP-2 (SHP2) protein. We previously generated knock-in mice harboring the PTPN11 mutation Y279C, one of the most common NSML alleles; these now-termed SHP2Y279C/+ mice recapitulate the human disorder and develop hypertrophic cardiomyopathy (HCM) by 12 weeks of age. Functionally, heart and/or cardiomyocyte lysates from SHP2Y279C/+ mice exhibit increased basal and agonist-induced AKT and mTOR activities. Here, we sought to determine whether we could reverse the hypertrophy in SHP2Y279C/+ mice using ARQ 092, an oral and selective allosteric AKT inhibitor currently in clinical trials for patients with PI3K/AKT-driven tumors or Proteus syndrome. We obtained echocardiographs of SHP2Y279C/+ and wildtype (SHP2+/+) littermates, either in the presence or absence of ARQ 092 at 12, 14, and 16 weeks of age. While SHP2Y279C/+ mice developed significant left ventricular hypertrophy by 12 weeks, as indicated by decreased chamber dimension and increased posterior wall thickness, treatment of SHP2Y279C/+ mice with ARQ 092 normalized the hypertrophy in as early as 2 weeks following treatment, with hearts comparable in size to those in wildtype (SHP2+/+) mice. In addition, we observed an increase in fractional shortening (FS%) in SHP2Y279C/+ mice, an effect of increased compensatory hypertrophy, which was not apparent in SHP2Y279C/+ mice treated with ARQ 092, suggesting functional improvement of HCM upon treatment with the AKT inhibitor. Finally, we found that ARQ 092 specifically inhibited AKT activity, as well as its downstream effectors, PRAS and S6RP in NSML mice. Taken together, these data suggest ARQ 092 may be a promising novel therapy for treatment of hypertrophy in NSML patients." @default.
• W2622765713 created "2017-06-15" @default.
• W2622765713 creator A5011466190 @default.
• W2622765713 creator A5045588447 @default.
• W2622765713 creator A5065746893 @default.
• W2622765713 creator A5076603975 @default.
• W2622765713 creator A5085043351 @default.
• W2622765713 creator A5091526303 @default.
• W2622765713 date "2017-06-05" @default.
• W2622765713 modified "2023-10-13" @default.
• W2622765713 title "In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy" @default.
• W2622765713 cites W1876597264 @default.
• W2622765713 cites W1983975259 @default.
• W2622765713 cites W2003823578 @default.
• W2622765713 cites W2008119136 @default.
• W2622765713 cites W2011253818 @default.
• W2622765713 cites W2078051911 @default.
• W2622765713 cites W2085012545 @default.
• W2622765713 cites W2107546866 @default.
• W2622765713 cites W2118719488 @default.
• W2622765713 cites W2128968389 @default.
• W2622765713 cites W2129317874 @default.
• W2622765713 cites W2130171501 @default.
• W2622765713 cites W2133770788 @default.
• W2622765713 cites W2134128731 @default.
• W2622765713 cites W2144738079 @default.
• W2622765713 cites W2159532830 @default.
• W2622765713 cites W2171908036 @default.
• W2622765713 cites W2292428979 @default.
• W2622765713 cites W2326886626 @default.
• W2622765713 cites W2404921371 @default.
• W2622765713 cites W2466008579 @default.
• W2622765713 cites W3192453023 @default.
• W2622765713 doi "https://doi.org/10.1371/journal.pone.0178905" @default.
• W2622765713 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5459472" @default.
• W2622765713 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28582432" @default.
• W2622765713 hasPublicationYear "2017" @default.
• W2622765713 type Work @default.
• W2622765713 sameAs 2622765713 @default.
• W2622765713 citedByCount "23" @default.
• W2622765713 countsByYear W26227657132018 @default.
• W2622765713 countsByYear W26227657132019 @default.
• W2622765713 countsByYear W26227657132020 @default.
• W2622765713 countsByYear W26227657132021 @default.
• W2622765713 countsByYear W26227657132022 @default.
• W2622765713 countsByYear W26227657132023 @default.
• W2622765713 crossrefType "journal-article" @default.
• W2622765713 hasAuthorship W2622765713A5011466190 @default.
• W2622765713 hasAuthorship W2622765713A5045588447 @default.
• W2622765713 hasAuthorship W2622765713A5065746893 @default.
• W2622765713 hasAuthorship W2622765713A5076603975 @default.
• W2622765713 hasAuthorship W2622765713A5085043351 @default.
• W2622765713 hasAuthorship W2622765713A5091526303 @default.
• W2622765713 hasBestOaLocation W26227657131 @default.
• W2622765713 hasConcept C104317684 @default.
• W2622765713 hasConcept C121608353 @default.
• W2622765713 hasConcept C126322002 @default.
• W2622765713 hasConcept C127716648 @default.
• W2622765713 hasConcept C134018914 @default.
• W2622765713 hasConcept C167414201 @default.
• W2622765713 hasConcept C2776149932 @default.
• W2622765713 hasConcept C2780185194 @default.
• W2622765713 hasConcept C2781187634 @default.
• W2622765713 hasConcept C31734879 @default.
• W2622765713 hasConcept C502942594 @default.
• W2622765713 hasConcept C526805850 @default.
• W2622765713 hasConcept C54355233 @default.
• W2622765713 hasConcept C62478195 @default.
• W2622765713 hasConcept C68838962 @default.
• W2622765713 hasConcept C71924100 @default.
• W2622765713 hasConcept C75217442 @default.
• W2622765713 hasConcept C86554907 @default.
• W2622765713 hasConcept C86803240 @default.
• W2622765713 hasConceptScore W2622765713C104317684 @default.
• W2622765713 hasConceptScore W2622765713C121608353 @default.
• W2622765713 hasConceptScore W2622765713C126322002 @default.
• W2622765713 hasConceptScore W2622765713C127716648 @default.
• W2622765713 hasConceptScore W2622765713C134018914 @default.
• W2622765713 hasConceptScore W2622765713C167414201 @default.
• W2622765713 hasConceptScore W2622765713C2776149932 @default.
• W2622765713 hasConceptScore W2622765713C2780185194 @default.
• W2622765713 hasConceptScore W2622765713C2781187634 @default.
• W2622765713 hasConceptScore W2622765713C31734879 @default.
• W2622765713 hasConceptScore W2622765713C502942594 @default.
• W2622765713 hasConceptScore W2622765713C526805850 @default.
• W2622765713 hasConceptScore W2622765713C54355233 @default.
• W2622765713 hasConceptScore W2622765713C62478195 @default.
• W2622765713 hasConceptScore W2622765713C68838962 @default.
• W2622765713 hasConceptScore W2622765713C71924100 @default.
• W2622765713 hasConceptScore W2622765713C75217442 @default.
• W2622765713 hasConceptScore W2622765713C86554907 @default.
• W2622765713 hasConceptScore W2622765713C86803240 @default.
• W2622765713 hasFunder F4320308605 @default.
• W2622765713 hasIssue "6" @default.
• W2622765713 hasLocation W26227657131 @default.
• W2622765713 hasLocation W26227657132 @default.
• W2622765713 hasLocation W26227657133 @default.
• W2622765713 hasLocation W26227657134 @default.

• next